The startup develops pharmaceutical technology for tumor immunity that utilizes multi-omics analysis, receptor ligand discovery, and antibody engineering to enhance drug efficacy. This approach enables the identification of novel therapeutic targets, improving precision medicine and treatment outcomes for patients with cancer.

Inhalon Biopharma is developing inhaled monoclonal antibody treatments for acute respiratory infections, including RSV and SARS-CoV-2, utilizing a novel inhalation delivery system. This approach aims to enhance treatment effectiveness and provide a convenient "test-to-treat" model for patients, facilitating timely and accessible respiratory care.

Saccharo is a preclinical oncology company developing therapies that target the polysaccharide dPSA, which is specifically expressed on cancer cells and linked to the nuclear protein nucleolin. This approach addresses the challenge of off-target toxicity and treatment resistance associated with conventional cancer therapies by providing a selective mechanism to kill cancer cells.

Trio Pharmaceuticals develops dual-targeting antibody drugs, TIE-ADC™ and TRAILBody™, that selectively eliminate cancer cells while overcoming tumor immunosuppression, thereby enhancing the immune response without harming healthy cells. This approach addresses the limitations of current cancer therapies, which often lack selectivity and can inadvertently damage normal tissues, leading to significant treatment-related toxicity.